SCHEMBL806149

SCHEMBL806149

O=Cc1ccc(N(c2ccc(C=O)cc2)c2ccccc2CCc2ccccc2N(c2ccc(C=O)cc2)c2ccc(C=O)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
ALDH1A3 P47895 4/20 0.48
ALDH3A1 P30838 4/20 0.48
CYP2A6 P11509 3/20 0.42
CYP2A13 Q16696 1/20 0.42
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 1/20 0.33
ALDH5A1 P51649 1/20 0.33
ABAT P80404 1/20 0.33
PTPN1 P18031 1/20 0.32
DRD2 P14416 1/20 0.32
DRD1 P21728 1/20 0.32
DRD4 P21917 1/20 0.32
DRD5 P21918 1/20 0.32
DRD3 P35462 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MAPT P10636 1/20 0.31
RAB9A P51151 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10028280 0.88 ALDH1A1 (0.53) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL7890756 0.86 ALDH1A1 (0.50) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL806152 0.78 ALDH1A1 (0.39) ALDH1A1KDM4EPTPN1DRD2DRD1
SCHEMBL7750867 0.76 ALDH1A1 (0.50) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL2199745 0.74 ALDH1A1 (0.59) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL851178 0.74 ALDH1A1 (0.59) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL181026 0.74 ALDH1A1 (0.59) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL13649928 0.74 ALDH1A1 (0.59) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL28032989 0.74 ALDH1A1 (0.59) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL12640411 0.74 RELA (0.47) ALDH1A1SMN1; SMN2MAPTRAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616883-B1 ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR, IMAGE FORMING METHOD, IMAGE FORMING APPARATUS, AND PROCESS CARTRIDGE RICOH CO LTD (JP) 2017-09-06 EP disclosed
US-8871412-B2 Electrophotographic photoconductor, image forming method, image forming apparatus, and process cartridge RICOH COMPANY, LTD. (JP) 2014-10-28 US disclosed
US-20130177842-A1 ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR, IMAGE FORMING METHOD, IMAGE FORMING APPARATUS, AND PROCESS CARTRIDGE RICOH COMPANY, LTD. (JP) 2013-07-11 US disclosed
WO-2012036295-A1 ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR, IMAGE FORMING METHOD, IMAGE FORMING APPARATUS, AND PROCESS CARTRIDGE RICOH COMPANY, LTD. (JP) 2012-03-22 WO disclosed
US-20120021346-A1 IMAGE BEARING MEMBER AND IMAGE FORMING METHOD, IMAGE FORMING APPARATUS, AND PROCESS CARTRIDGE USING SAME RICOH COMPANY, LTD. (JP) 2012-01-26 US disclosed
US-20110200926-A1 ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR, IMAGE FORMING METHOD, IMAGE FORMING APPARATUS, AND PROCESS CARTRIDGE RICOH COMPANY, LTD. (JP) 2011-08-18 US disclosed
US-20110081607-A1 METHYLOL COMPOUND, ALDEHYDE COMPOUND, METHOD FOR PREPARING THE METHYLOL COMPOUND USING THE ALDEHYDE COMPOUND, AND PHOTORECEPTOR USING THE METHYLOL COMPOUND RICOH COMPANY, LTD., (JP) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081607-A1 METHYLOL COMPOUND, ALDEHYDE COMPOUND, METHOD FOR PREPARING THE METHYLOL COMPOUND USING THE ALDEHYDE COMPOUND, AND PHOTORECEPTOR USING THE METHYLOL COMPOUND ALDH1A2, MGMT, MCOLN2 ALDH1A1 98/4885ALDH1A3 12/4885ALDH3A1 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.